培训资料下载中心
在线调研中心

  • 胡爱荣
    宁波肝病医院
    “我成功因为我志在成功!”
  • 郑小庆
    宁波肝病医院
    “尽自己所能,让自己满意!”
  • 谭俊
    宁波肝病医院
    “年轻没有失败,只要亮出风采!“
  • 李建芳
    宁波肝病医院
    “人之所以能,是相信能!“
  • 李明
    南昌大学附一医院
    “爱拼才会赢!”
  • 钟渊斌
    南昌大学附一医院
    “只要有斗志,不怕没战场。”
  • 张文峰
    南昌大学附一医院
    “自古成功在尝试。”
  • 高海兵
    福州传染病医院
  • 张元芬
    福州传染病医院
  • 郑玲
    福州传染病医院
  • 黄祖雄
    福州传染病医院
  • 陈洁
    福建175 医院
  • 陈雪婉
    福建175 医院
  • 徐成润
    福建175 医院
  • 何芳
    四川大学华西医院
  • 刘凯
    四川大学华西医院
  • 卢家桀
    四川大学华西医院
  • 王丽春
    四川大学华西医院
  • 张琼
    成都市传染病医院
  • 朱丽
    成都市传染病医院
  • 张鸿
    成都市传染病医院
  • 王莉妮
    成都市传染病医院
       

培训资料当前位置:首页知识传递 > 培训资料 >

The economics of treating chronic hepatitis B in Asia

来源: 作者:Yock Young Dan 时间:2009-06-09 点击:

Yock Young Dan Myat Oo AungSeng Gee Lim

Received: 16 November 2007 / Accepted: 18 January 2008 / Published online: 1 May 2008_ Asian Pacific Association for the Study of the Liver 2008

Abstract Chronic hepatitis B constitutes a significant health and economic burden to Asian countries. Six medications are now approved for the treatment of chronic hepatitis B, but there is still significant uncertainty with regards to treatment outcomes, cost impact, and benefits in view of the absence of long-term outcomes data. Cost effectiveness Markov modeling thus allows us to project and estimate long-term outcomes based on current data and compare the cost-benefit between different treatment options. However, there are limitations to these reported studies. Cost-utility indices such as cost/quality-adjusted life years (cost/QALY) may not be intuitive to clinicians and patients. These studies are also usually based on first world economies, using a benchmark of US$50,000/ QALY, and cannot be extrapolated directly to Asia-Pacific countries. Cost-effectiveness of various treatment strategies using a combination of cost-effectiveness indices may provide a more complete picture. These include cost/HBeAg seroconversion for HBeAg-positive patients (range: US$19,400-30,800) and cost/HBV DNA negative(PCR assay) for HBeAg-negative patients (range: US$14,400-32,000) over 5-year time horizon; cost per cirrhosis prevented (range: US$326,000-686,000) and cost per HCC prevented (range: US$654,000-1,380,000) over 10-year horizon using data from REVEAL study, cost per end point complication prevented in cirrhotics (US$9,630/ year), and cost per HCC prevented in cirrhotics (US$ 27,600/year) over a 32-month horizon, using data from Asia Lamivudine Cirrhosis Study. More potent antivirals with low resistance appear to have lower cost/clinical end point averted. Published reports of cost-utility analysis comparing treatment using conventional cost/QALY show that all treatment modalities fall below the first-world benchmark of US$50,000/QALY but vary in modeling assumptions and in quality, making comparisons difficult. Reimbursement policies affect out-of-pocket expenses to the patient, and increases the proportion of patients who can afford therapy, but generally do not affect cost-effectiveness. In conclusion, cost-effectiveness analysis is an important tool for health care administrators, clinicians, and patients to decide on the optimal therapy for chronic hepatitis B, but the methodology permits considerable leeway for interpretation of results, thus a combination of cost-effective indices may be needed to paint a more complete picture.

Keywords  Hepatitis B treatment Cost-effectiveness analysis

论坛内相关帖子:

The economics of treating chronic hepatitis B in Asia


最新评论共有 11 位网友发表了评论
发表评论
评论内容:不能超过250字,需审核,请自觉遵守互联网相关政策法规。
用户名: